Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.

Authors

Institutions

Publication Details

Journal
British Journal of Nursing
Published
2025-04-19
DOI
https://doi.org/10.12968/bjon.2025.34.sup10b.s4
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Elaine Tomlins, Jenna Robinson, Sallie Long, Caroline Harnett et al.
1 links
British Journal of Nursing
Biosimilars and Bioanalytical Methods
article

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Elaine Tomlins, Jenna Robinson, Sallie Long, Caroline Harnett, Sarah E. Sheppard, S. J. Pickering, Sean Dulloo, Anna Claire Olsson-Brown, Helen Winter
article en

Abstract

Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.

British Journal of NursingVol. 34(Sup10b)
Barking, Havering And Redbridge University Hospitals NHS Trust (GB), Royal Marsden NHS Foundation Trust (GB), University of Hull (GB), Peterborough City Hospital (GB), University Hospitals Bristol NHS Foundation Trust (GB), University Hospitals of Leicester NHS Trust (GB), University Teaching Hospital (ZM), University Hospitals Sussex NHS Foundation Trust (GB), Torbay and South Devon NHS Foundation Trust (GB), University Hospitals Bristol and Weston NHS Foundation Trust (GB)
Openalex Percentile: Top 91%
Biosimilars and Bioanalytical Methods
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies — Elaine Tomlins, Jenna Robinson, et al. · British Journal of Nursing (2025) | TGRS Research Map | TGRS